Inhibitors of Akt activity

US7910561B2 · kind B2 · utility

Assignee

• Merck Sharp & Dohme LLC · US

Inventors

• Jeannie M. Arruda · San Diego, US
• Brian T. Campbell · Souderton, US
• Nicholas D. P. Cosford · San Diego, US
• Jacob M. Hoffman · Lansdale, US
• Essa Hu · Camarillo, US
• Mark E. Layton · Harleysville, US
• Yiwei Li · Ambler, US
• Jun Liang · Los Altos Hills, US
• Kevin J. Rodzinak · Valdosta, US
• Tony Siu · Brookline, US
• Brian Andrew Stearns · Encinitas, US
• Lida Tehrani · San Diego, US
• Mark T. Bilodeau · Waltham, US
• Peter J. Manley · Harleysville, US

Key dates

• Filing date: Dec 9, 2005
• Grant date: Mar 22, 2011
• Expiry date: Jul 15, 2028

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention is directed to compounds which contain substituted naphthyridines which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer comprising administration of the compounds of the invention. These substituted naphthyridines have unexpected advantageous properties when compared to other naphthyridines reported in PCT publication WO2003/086394, such unexpected advantageous properties may include increased cellular potency/solubility, greater selectivity, enhanced pharmacokinetic properties, lack of off target activity and so on.